engleski

Cytoreductive surgery and hyperthermic intraperitoneal perioperative chemotherapy: initial results

Background. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal perioperative chemotherapy (HIPEC) improves survival in large volume low-grade tumors such as in pseudomyxoma peritonei and survival in carefully selected patients with high-grade cancers such as ovarian and appendiceal adenocarcinoma, gastric and colorectal cancer. Methods. Seven patients underwent CRS and HIPEC in first year, 5 females and 2 males age 43–75 (median 56.4). Four patients had pseudomyxoma peritonei originating from appendiceal mucinous adenocarcinoma, 3 had carcinomatosis peritonei caused by ovarian cancers. Results. Adequate cytoreduction was performed in all patients. Two patients died in early postoperative period (14th and 42nd day). Other five patients are evaluated every three months and are in good clinical condition without evidence of recurrent disease. Conclusions. CRS with HIPEC significantly improves survival of patients with peritoneal carcinomatosis and pseudomyxoma peritonei. However during intorduction period higher morbidity and mortality could expected.

Cytoreductive surgery ; Hyperthermic intraperitoneal perioperative chemotherapy

nije evidentirano